Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Children's Hospital Boston
University of California, San Francisco
Ann & Robert H. Lurie Children's Hospital of Chicago
Children's Healthcare of Atlanta
Children's Hospital Colorado
Children's Hospital Los Angeles
Children's Hospital of Michigan
Children's Hospitals and Clinics of Minnesota
Cook Children's Medical Center
Doernbecher Children's Hospital
Duke University
Johns Hopkins University
Miami Children's Hospital
Nemours Children's Clinic Jacksonville
New York University
Milton S. Hershey Medical Center
Seattle Children's
Stanford University/Lucile Packard Children's Hospital
University of Louisville
UT Southwestern Medical Center
Washington University School of Medicine
Phoenix Children's Hospital
Information provided by (Responsible Party):
Mark W. Kieran, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01182350
First received: August 12, 2010
Last updated: November 18, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)